SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is drawing heavy speculative attention after founder Patrick Soon-Shiong teased blockchain-based tokenized stock trading at Nant, with bullish traders framing potential IBRX tokenization as a curb on naked short selling that could pressure what they view as a heavily shorted float. Skeptics counter that the tease is not a confirmed company announcement and call it a distraction from fundamentals, pointing instead to Anktiva's upcoming PDUFA review, while unverified chatter about Soon-Shiong meeting Turkey's president adds speculation about a possible Anktiva expansion there.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is drawing heavy attention after reporting positive Phase 2 maintenance data for VK2735, with bulls calling the obesity results best-in-class versus Zepbound and retatrutide while others point to the muted price reaction, elevated short interest, and squeeze potential as the real story. Traders are also reviving unconfirmed buyout and partnership speculation, including chatter that Novo Nordisk could be a suitor, though no deal has been confirmed.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Traders are focused on Innodata's push into AI security and model evaluationhighlighted by the board appointment of former NSA Director Michael Rogers and Innodata Muse red-teaming coveragewhich many frame as a bullish catalyst for the stock's surge, while others argue the move is technical momentum and not news-driven at all. The broader thread reflects a persistent split, with bulls citing real revenue acceleration and a government AI-evaluation runway and bears pointing to bear-flag patterns, weak support, and a possible short-term breakdown.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is drawing heavy retail attention after CEO Ryan Cohen added roughly $26.4 million in open-market share purchases, with traders speculating the insider buying points to a larger company buyback ahead. The conversation skews bullish, mixing short-squeeze hopes and warrant-related price levels, though some traders counter that short interest has declined and question why the stock has not rallied more in line with the CEO's confidence.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

Royal Caribbean's acquisition of all-inclusive resort operator Sandals is dominating the conversation, with many traders criticizing the deal's timing and cost as the stock sells off  some even calling for management to be ousted  while others argue the price is fair and are buying the dip. Several traders also voiced confusion over the decline, noting it came even as oil prices fell, adding to frustration with the broader cruise-sector slump.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is drawing heavy attention as shares extend a steep, months-long slide around its removal from the S&P 500, with traders debating whether index-driven selling, exceptionally heavy short interest, or slowing growth  including a quarterly revenue outlook traders cite as cut to roughly $650 million  best explains the decline. Sentiment is overwhelmingly bearish, with repeated criticism of CEO Jeff Green and management, though a vocal minority argues the stock's oversold condition and large short base could fuel a sharp rebound if any positive catalyst emerges.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

OMER is surging to multi-year highs after Cantor Fitzgerald upgraded the stock to Overweight, citing a stronger-than-expected commercial launch for its lead drug Yartemlea and raising its peak sales expectations. Traders are debating whether the rally reflects more than the upgrade, pointing to additional potential catalysts such as the Medicare add-on payment taking effect, an anticipated Novo Nordisk milestone payment, and the European re-examination of Yartemlea.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending on debate over its satellite deployment pace: some traders cite third-party tracking data as evidence that BlueBird 11 is testing maneuvers or beginning to unfold its arrays, while skeptics counter that its deployment remains unconfirmed and that shipments and launches of the next BlueBirds have slipped. Frustration with the company's sparse communication  and an update bears framed as negative  has sharpened the bull-versus-bear clash, with chatter about coordinated short campaigns and a securities class action also circulating.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as traders question why the stock keeps selling off at the open and finishing red despite a run of positive company news, most notably CEO Dara Khosrowshahi's roughly $10 million open-market share purchase alongside additional COO insider buying that many in the community read as a strong accumulation signal. Reaction is split between bulls citing the insider purchases, new delivery partnerships, and Bill Ackman's backing as reasons to buy the weakness, and skeptics who suspect manipulation, sustained short pressure, or legitimate concern that Tesla and Waymo autonomous-vehicle competition threatens Uber's core business.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after crossing the $1 trillion market-cap milestone for the first time on a sharp surge to record highs, with traders crediting AI demand optimismfueled by the strong reception of Meta's Muse AI agent and bets that agentic AI workloads will drive CPU and chip demand. Retail sentiment has turned extremely bullish amid short-squeeze speculation and calls for further upside, while skeptics warn of stretched valuations, potential dilution from low-exercise-price warrants issued to OpenAI and Meta, and insider share sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

Equity

RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial. 

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.read more...

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Dyne Therapeutics Stock Tumbles After Hours: Here's Why

Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.


SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.


DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026...

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Key PointsDyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform...

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Bearish Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DYN Dyne Therapeutics Inc

Fundamentals

Latest DYN News